Week Ending September 19, 2022

Scientists find clues to how air pollution may trigger lung cancer
“Scientists have long known that air pollution can be linked with an increased risk of lung cancer in people who never smoked, but new research describes one mechanism that might help explain how.”

Lung Cancer Screening Increases Percentage of Stage I Cases Detected, While Reducing Percentage of Stage IV Cases Detected
“Implementing lung cancer screening at four diverse health-care systems resulted in an 8.4% increase in the number of stage I lung cancers detected and a 6.6% decrease in the detection of stage IV disease, according to research published by Vachani et al in the Journal of Thoracic Oncology.”

Lung Cancer Screening Leads to Earlier Diagnosis, but Not Overdiagnosis
“A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated. Newly released data is adding to the case that lung cancer screening results in earlier identification of lung cancer, and it may help allay concerns about a corresponding risk of overdiagnosis.”

Mark A. Socinski, MD, on Progression of Lung Cancer Treatment
“The treatment of lung cancer has evolved greatly over the last 30 years. Recently, numerous therapy modalities have been tested and successfully implemented into earlier stages of treatment as either adjuvant or neoadjuvant therapy. Additionally, clinicians across the cancer care paradigm are learning how to better tailor treatment to patients based on their genetic makeup.”

Study Finds High Activity With Poziotinib in Non-Small Cell Lung Cancer with HER2 Exon 20 Insertion Mutations
“New data from a trial of poziotinib in non-small cell lung cancer (NSCLC) with G778_P780dup HER2 exon 20 insertion (exon20ins) mutations found that the drug had high activity in both treatment-naïve and previously treated patients. The data are being presented at the European Society for Medical Oncology Congress 2022.”

Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer
“Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) demonstrated clinically meaningful tumor responses in previously treated patients with human epidermal growth factor receptor 2 mutant (HER2m) unresectable and/or metastatic non-squamous non­–small cell lung cancer (NSCLC), according to detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial.”

Osimertinib Significantly Improves Disease-Free Survival in EGFR-Mutated Lung Cancer
“Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.”

Lumakras Improves Outcomes, Quality of Life in Patients With Lung Cancer Subtype
“Lumakras (sotorasib) decreased the risk of disease progression or death by 34% in patients with previously treated non-small cell lung cancer (NSCLC), and the drug led to more patients being alive without disease progression at 12 months (a statistic known as progression-free survival) compared to the chemotherapy docetaxel, according to findings from the phase 3 CodeBreaK 200 clinical trial.

Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal

Looking at the Future of Larotrectinib in NTRK Fusion+ Lung Cancer